TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05954442
Drug: Investigator's Choice of Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice of chemotherapy means the chemotherapy chosen by investigators/doctors to treat metastatic triple negative breast cancer, including nab-paclitaxel, capecitabine, eribulin, carboplatin, vinorelbine, or utidelone.
Study: NCT05551832
Drug: Arm I (Placebo),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo after Pylurus preserving Pancreaticoduodenctomy (PPPD) for 6 months
Study: NCT05551832
Drug: Arm II (ESMESOL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMESOL 40 mg dose administrea daily at bedtime for 6 months after PPPD ,
Study: NCT04994951
Drug: Triamcinolone Acetonide Acetate and Urea Cream.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10g/tube and CalcipotriolOintment,10g/tube are used alternately.
Study: NCT04994951
Drug: Qing-Re-Liang-Xue Decoction.
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of granules is mixed, poured into 500ml of boiling water, and taken twice in the morning and afternoon. Women stop taking Chinese medicine during the first 3 days of menstruation.The period of treatment will be 10 weeks.
Study: NCT00000885
Drug: Levocarnitine
Normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05244798
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with TP regimen: albumin-paclitaxel + carboplatin, D1 administration) for 2 cycles. Every 3 weeks was a dosing cycle (Q3W).
Study: NCT05106309
Drug: 10 mg CVL-231 as IR formulation
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT05106309
Drug: 30 mg CVL-231 Target Release, Fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT01411254
Drug: Betamethasone Microsphere (DE-102） Low Dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01411254
Drug: Betamethasone Microsphere (DE-102） High Dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05007132
Drug: Trifluridine/Tipiracil Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive Trifluridine/tipiracil at 35 mg/m² BSA, twice daily, orally on days 1-5 and 8-12
Study: NCT01411254
Drug: Sham
Normalized name: SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05279742
Drug: MANP
Normalized name: Multimineral/Multivitamin Oral Tablet [MANPOWER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous injection 5 µg/Kg
Study: NCT05279742
Drug: Injection Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous injection that contains no active ingredient
Study: NCT05251090
Drug: FRSW107
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 IU/kg, a single dose.
Study: NCT04749459
Drug: ISO 24444:2010 P2 Standard Reference Sunscreen
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single topical application of ISO 24444:2010 P2 Standard Sunscreen will be applied to the appropriate 40 cm\^2 test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 mg/cm\^2, using 80 +/-2 mg of material.
Study: NCT05376176
Drug: STN1010904 ophthalmic suspension 0.03% BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% STN1010904 ophthalmic suspension BID
Study: NCT05376176
Drug: STN1010904 ophthalmic suspension 0.1% BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% STN1010904 ophthalmic suspension BID
Study: NCT05376176
Drug: Placebo (Vehicle) BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle) BID
Study: NCT06047483
Drug: HRF2105 patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRF2105 patch ，external use，once a day
Study: NCT06047483
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo ，external use，once a day
Study: NCT05630209
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin infusion
Study: NCT05521230
Drug: Placebo Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of mouthwashes
Study: NCT05521230
Drug: Cymenol mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of mouthwashes
Study: NCT05209633
Drug: Granules Dendrobii
Normalized name: Dendrobium moniliforme whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6g each, 3 times per day, total 18 weeks
Study: NCT05209633
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04839731
Drug: Combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply twice per day for allotted time
Study: NCT04839731
Drug: Nourivan Base Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply twice per day for allotted time
Study: NCT05245760
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC2) and Paclitaxel (50mg/m2), Weekly x 5 weeks
Study: NCT06560528
Drug: combination with Disitamab Vedotin and with Tislelizumab and Capecitabine
Normalized name: Disitamab vedotin
DrugBank: Disitamab vedotin (DB17208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive Disitamab Vedotin combined with Tislelizumab and Capecitabine for 3 cycles (Q3W) in the neoadjuvant phase and 5 cycles (Q3W) of treatment in the adjuvant phase.~1. Disitamab Vedotin：2.5 mg/kg，Q3W；~2. Tislelizumab：200 mg，Q3W；~3. Capecitabine：1000 mg /m2, PO, bid d1-14, Q3W.
Study: NCT06338956
Drug: LDL reduction therapy
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL reduction therapy
Study: NCT02317263
Drug: testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02317263
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05677555
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 25 subjects will be randomized to treatment with matched placebo, three times a week (at the end of each hemodialysis session) over the 3 month study period.
Study: NCT06281184
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 10-20 mg x 1 per week, combined with folic acid 1mg daily.
Study: NCT05551273
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet
Study: NCT05560646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive (orally) OG-6219 Placebo tablets BID during treatment cycles.
Study: NCT05786924
Drug: BDTX-4933
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III) and constitutively active CRAF, KRAS or NRAS mutations
Study: NCT05016323
Drug: HR19042 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR19042 Capsules
Study: NCT05016323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05374538
Drug: VIC-1911
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIC-1911 tablets for oral administration
Study: NCT05407584
Drug: Orevogomab+PLD
Normalized name: pLDLR-Neo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD (40 mg / m2 IV over three hours in one day) to be repeated till progression or unacceptable toxicity every four weeks (28 days)~Investigational agent (Oregovomab): 2 mg diluted in 50 mL saline for injection administered IV following PLD over approximately 20 (acceptable range 15-30) minutes for a total of 5 scheduled injections, one each at Cycle 1, Cycle 2, Cycle 3, Cycle 5, and Cycle 7
Study: NCT04870606
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo+Standard of care determined by PI and local regulatory
Study: NCT02054260
Drug: Surgicel
Normalized name: Surgicel SNoW 4x4"
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05988671
Drug: normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal route
Study: NCT05965284
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients included into this study will be treated with Azathioprine tablets 100mg QD for 12 months.
Study: NCT06428669
Drug: Nitro-Bid 2 % Topical Ointment
Normalized name: Nitro-Bid 2 % Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group will get 30mg of Nitro-Bid topical ointment applied over the chest (15mg/ 1 packet on each side) one time intra-operatively
Study: NCT05098990
Drug: Jinfukang oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinfukang koufuye is a Chinese herbal prescription, which is used in treatment for patients with NSCLC in clinical practice. It has been proved to be capable of preventing the occurrence of metastasis, stabilizing tumor lesions, improving the response rates when combined with chemotherapy, and prolonging the survival period of lung cancer patients.
Study: NCT05667129
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule formulation
Study: NCT05433857
Drug: Lacteol forte capsules
Normalized name: Erythroped Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: probiotic Lacteol Forte® capsules (5 billion heat-killed Lactobacillus LB, corresponding to lactobacillus delbruekii and lactobacillus fermentum) Two capsules are To be taken once daily
Study: NCT05091320
Drug: medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: medical management of patient according guide lines, either alteplase if presented in it's time window, or anti-platelet
Study: NCT04756713
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional chemotherapy will be treated with MTX (1 mg/kg intramuscular) with rescue of FA (15mg orally). In cases of chemoresistance, second-line chemotherapy will be performed with actinomycin-D (Act-D) 1.25 mg intravenous pulse every 14 days. The third line of chemotherapy will be the EMA/CO regimen (, reserving the EP / EMA regimen (E, cisplatin, MTX / Act-D) for the fourth line.
Study: NCT05429567
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients underwent combined spinal and epidural anesthesia (CSEA) with 2 ml of 0.5 % hyperbaric bupivacaine and 25 ug fentanyl administered using a 27-gauge Whitacre spinal needle and an 18-gauge Tuohy needle in the epidural space. The epidural space was identified utilizing the loss of resistance approach
Study: NCT04738539
Drug: Contrast Enhanced Voiding Urosonography with Urodynamic Testing
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: We will be using contrast enhanced voiding urosonography to image urodynamic testing on patients with neurogenic bladder.
Study: NCT06093932
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 capsules at a time, three times a day, duration: 12 weeks
Study: NCT05555017
Drug: ADT
Normalized name: Radtue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 6 months of ADT according to current clinical guidelines. ADT consists of one subcutaneous depot of 22,5mg triptorelin (Pamorelin), with 4 weeks bicalutamide 50mg per os from 2 weeks before till 2 weeks after the first Pamorelin administration.
Study: NCT05641324
Drug: ANV419
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANV419 administered by intravenous (IV) infusion
Study: NCT05957991
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with placebo
Study: NCT04906980
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo (PEG400) will be administered orally.
Study: NCT06400355
Drug: Ringer's Lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: similar volume of the infused mannitol but of lactated Ringer will be given 30 minutes before the end of the surgery.
Study: NCT05108779
Drug: QLF32004
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the phase, five dose groups were proposed.The frequency of administration was once a week, and the treatment cycle was 3 weeks.
Study: NCT05170594
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: The non-platinum chemotherapy regimen will be determined by the investigator.
Study: NCT04879043
Drug: HDP-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDP-101 is available as lyophilized white powder for preparation of infusion.
Study: NCT05622526
Drug: Group 1 or Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules of fecal microbiota transplantation
Study: NCT06206174
Drug: TGRX-814
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are given TGRX-814 tablets for oral, once daily administration at one of the dose levels as pre-determined for the dose escalation sequence.
Study: NCT05099471
Drug: DRC
Normalized name: DRC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Dexamethasone / Rituximab / Cyclophosphamide
Study: NCT05294055
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 50mg/kg or 2g/m2, for 2 days
Study: NCT05716880
Drug: Ketosteril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose = 1 tabl / 5 kg of ideal body weight
Study: NCT06515405
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cohort members will be considered to be exposed to early hydrocortisone if either:~1. They receive early hydrocortisone started on postnatal day 1 or 2 and given for more than seven consecutive days OR~2. They receive early hydrocortisone started on postnatal day 1 or 2 and are being cared for in a PROHYDRO unit but die on or before postnatal day 8.~PROHYDRO units are defined as units who, at the time the baby was born, had implemented a protocol for use of prophylactic hydrocortisone as part of routine care for babies born less than 28 weeks' gestation. A unit may change from being a non-PROHYDRO unit to a PROHYDRO unit if a new early hydrocortisone protocol is introduced during the study period (2016-2023).
Study: NCT06206759
Drug: administration of vitamin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of vitamin C to ICU patients
Study: NCT04704232
Drug: ACD440
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double blind, parallel within subject comparison
Study: NCT04766021
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control condition
Study: NCT05172947
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group received placebo with the conventional therapy
Study: NCT05169710
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet (supplied in two tablets)
Study: NCT05841043
Drug: SHR8028 eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR8028 eye drops
Study: NCT05841043
Drug: Vehicle eye drops.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle eye drops.
Study: NCT06443151
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endothelium-dependent vasodilation will then be assessed by changes in FBF in response to intra-arterial infusions of the endothelial agonist acetylcholine infused at rates of 4.0, 8.0, 16.0 μg/100 mL of forearm tissue/min to generate a dose-response curve.
Study: NCT06443151
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid will be infused at a constant rate (12 mg/100 mL tissue/min) and maintained at the same rate while the acetylcholine and sodium nitroprusside dose-response curves are repeated.
Study: NCT06233071
Drug: Drospirenone+ Ethinyl Estradiol Tablets-Test product
Normalized name: drospirenone / ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Manufactured by: POND'S CHEMICAL THAILAND R.O.P
Study: NCT06233071
Drug: Drospirenone+ Ethinyl Estradiol Tablets-Reference product
Normalized name: drospirenone / ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Manufactured by: Bayer Weimar GmbH und Co. KG, Germany
Study: NCT01868048
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oromucosal spray, containing no active drug but ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorants. Maximum permitted dose is 10 actuations per day.
Study: NCT04739046
Drug: Theragene arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theragene®,Ad5-yCD/ mutTKSR39rep-ADP with radiation therapy
Study: NCT04678440
Drug: [18F]F-AraG Imaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total body PET imaging using \[18F\]F-AraG
Study: NCT06558708
Drug: GZR101 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily
Study: NCT06558708
Drug: GZR33 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily
Study: NCT05797701
Drug: SAR443820
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet by oral administration
Study: NCT05893576
Drug: HRS9531
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive a single dose of HRS9531 of original formulation.
Study: NCT06168214
Drug: Rabeprazloe+bismuth+amoxicillin+clarithromycin
Normalized name: lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PBAC: 14D: PPI: Rabeprazole 10mg bid; B: bismuth potassium citrate240mg bid/ colloidal bismuth pectin 300mg bid/ colloidal bismuth tartrate 220mg bid; A:amoxicillin1000mg bid; C: clarithromycin 500mg bid.
Study: NCT06168214
Drug: Vonoprazan+amoxicillin+clarithromycin 14 days
Normalized name: clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VAC14: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg bid; C: clarithromycin 500mg bid.
Study: NCT05797701
Drug: SAR443820
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule by oral administration
Study: NCT05920876
Drug: QLS32015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive subcutaneous (SC) injection of QLS32015. Eight dose groups were proposed, 21 days as a treatment cycle.
Study: NCT04631562
Drug: ALXN1820 SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALXN1820 SC will be administered as a manual SC push or SC infusion via a syringe pump. Doses will range from 12.5 milligrams (mg) to a maximum of 2250 mg. Multiple dosing duration will range from 3 to 5 weeks.
Study: NCT04631562
Drug: ALXN1820 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALXN1820 IV (450 mg) will be administered as an IV infusion.
Study: NCT04631562
Drug: Placebo SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo SC will be administered as a manual SC push or SC infusion via a syringe pump.
Study: NCT04631562
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV will be administered as an IV infusion.
Study: NCT06380816
Drug: UCB4594
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive UCB4594 as an intravenous infusion once every 3 weeks for up to 18 cycles, with each cycle lasting 21 days (\~1 year).
Study: NCT05893576
Drug: HRS9531
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive a single dose of HRS9531 of new formulation.
Study: NCT06168214
Drug: Vonoprazan+amoxicillin+clarithromycin 7 days
Normalized name: AMOXICILLIN/CLARITHROMYCIN/VONOPRAZAN
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC7: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg bid; C: clarithromycin 500mg bid.
Study: NCT06168214
Drug: Vonoprazan+tetracycline+furazolidone 14 days
Normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VTF14: 14D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.
Study: NCT05042310
Drug: LY3541860
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered either IV or SC.
Study: NCT05042310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered either IV or SC.
Study: NCT06168214
Drug: Vonoprazan+tetracycline+furazolidone 7 days
Normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VTF7: 7D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.
Study: NCT06168214
Drug: Vonoprazan+amoxicillin+tetracycline 14 days
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: hVAT: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid; T: tetracycline 500mg tid.
Study: NCT06099652
Drug: 611 300 mg Q2W
Approvals — FDA: no, EMA: no, PMDA: no
Description: 611 subcutaneous (SC) injection
Study: NCT06099652
Drug: 611 450 mg Q2W
Approvals — FDA: no, EMA: no, PMDA: no
Description: 611 subcutaneous (SC) injection
Study: NCT06099652
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo subcutaneous (SC) injection
Study: NCT06216639
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 500 mg film-coated tablets. Prescribed only for the primary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection who are allergic to penicillin. The prescribed daily dose is 500 mg BID for a period of 14 days.
Study: NCT06103201
Drug: Hyperpolarized 13C-Pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, traumatic brain injury.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, which refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\].
Study: NCT06009874
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will be treated with a placebo tab once daily for three months
Study: NCT05751265
Drug: 5Fu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 5-FU, 2.4 g/m2，bid，d1-d14，q3w
Study: NCT06383273
Drug: Placebo sublingual tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each dose of placebo will be provided as a matching sublingual tablet, containing placebo. Participants will receive 1 sublingual tablet of study medication 30 (± 5) minutes prior to planned surgery start, without food or water.